Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Invested Capital (2016 - 2025)

Karyopharm Therapeutics filings provide 14 years of Invested Capital readings, the most recent being -$271.9 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 46.18% to -$271.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$271.9 million, a 46.18% decrease, with the full-year FY2025 number at -$271.9 million, down 46.18% from a year prior.
  • Invested Capital hit -$271.9 million in Q4 2025 for Karyopharm Therapeutics, down from -$256.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of -$16.7 million in Q4 2022 to a low of -$271.9 million in Q4 2025.
  • Median Invested Capital over the past 5 years was -$129.1 million (2021), compared with a mean of -$132.6 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 79.09% in 2022 and later tumbled 717.76% in 2023.
  • Karyopharm Therapeutics' Invested Capital stood at -$79.7 million in 2021, then skyrocketed by 79.09% to -$16.7 million in 2022, then crashed by 717.76% to -$136.2 million in 2023, then plummeted by 36.57% to -$186.0 million in 2024, then tumbled by 46.18% to -$271.9 million in 2025.
  • The last three reported values for Invested Capital were -$271.9 million (Q4 2025), -$256.8 million (Q3 2025), and -$232.7 million (Q2 2025) per Business Quant data.